RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ilyang Pharmaceutical Co Stock

Ilyang Pharmaceutical Co Liabilities 2025

Ilyang Pharmaceutical Co Liabilities

232.5 B KRW

Ticker

007570.KS

ISIN

KR7007570005

In 2025, Ilyang Pharmaceutical Co's total liabilities amounted to 232.5 B KRW, a -11.78% difference from the 263.53 B KRW total liabilities in the previous year.

Ilyang Pharmaceutical Co Aktienanalyse

What does Ilyang Pharmaceutical Co do?

Ilyang Pharmaceutical Co Ltd is a leading South Korean company specializing in the development, manufacturing, and marketing of pharmaceutical products. The company was founded in 1941 and has since achieved a long and successful journey. Due to the dynamic growth of the national and international market, Ilyang Pharmaceutical Co Ltd has developed a wide range of products and services that enable the company to serve its customers worldwide. The company's business model is based on close collaboration between the departments of research & development, quality control, production, sales, marketing, and administration. The company aims to provide its customers with innovative, reliable, and high-quality products. One of the main divisions of Ilyang Pharmaceutical Co Ltd is the development and manufacturing of prescription drugs. The company is known for its research and development of drugs to address major global challenges such as cancer, diabetes, and cardiovascular diseases. Another important division of the company is the development and manufacturing of dietary supplements. These products are designed to improve the physical and mental health of people and enhance well-being. In addition to pharmaceutical products and dietary supplements, the company also offers a wide range of cosmetic products. These include anti-aging creams, sunscreen, hair care products, as well as skincare and nail care products. In recent years, Ilyang Pharmaceutical Co Ltd has also expanded its business activities internationally. The company has formed partnerships with various pharmaceutical companies in Europe, North America, and Asia to distribute its products worldwide. In addition to its commitment to the development and manufacturing of high-quality products, the company is also dedicated to sustainability and environmental protection. Ilyang Pharmaceutical Co Ltd has taken measures to reduce energy consumption and CO2 emissions in its production facilities. Furthermore, the company has demonstrated its responsibility for a clean environment through the introduction of innovative recycling solutions. In summary, Ilyang Pharmaceutical Co Ltd is a renowned company in the field of pharmaceutical products, dietary supplements, and cosmetics. The company has earned an excellent reputation for its innovative products and services as well as its commitment to sustainability and environmental protection. Ilyang Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Ilyang Pharmaceutical Co's Liabilities

Ilyang Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ilyang Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ilyang Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ilyang Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ilyang Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ilyang Pharmaceutical Co stock

What is the level of liabilities of Ilyang Pharmaceutical Co this year?

Ilyang Pharmaceutical Co has a debt balance of 232.5 B KRW this year.

What were the liabilities of Ilyang Pharmaceutical Co compared to the previous year?

The liabilities of Ilyang Pharmaceutical Co have increased by -11.78% dropped compared to the previous year.

What are the consequences of high debt for investors of Ilyang Pharmaceutical Co?

High liabilities can pose a risk for investors of Ilyang Pharmaceutical Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Ilyang Pharmaceutical Co?

Low liabilities mean that Ilyang Pharmaceutical Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Ilyang Pharmaceutical Co affect the company?

An increase in liabilities of Ilyang Pharmaceutical Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Ilyang Pharmaceutical Co affect the company?

A decrease in the liabilities of Ilyang Pharmaceutical Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Ilyang Pharmaceutical Co?

Some factors that can influence the liabilities of Ilyang Pharmaceutical Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Ilyang Pharmaceutical Co so important for investors?

The liabilities of Ilyang Pharmaceutical Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Ilyang Pharmaceutical Co take to modify the liabilities?

To change its liabilities, Ilyang Pharmaceutical Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Ilyang Pharmaceutical Co pay?

Over the past 12 months, Ilyang Pharmaceutical Co paid a dividend of 150 KRW . This corresponds to a dividend yield of about 1.23 %. For the coming 12 months, Ilyang Pharmaceutical Co is expected to pay a dividend of 150 KRW.

What is the dividend yield of Ilyang Pharmaceutical Co?

The current dividend yield of Ilyang Pharmaceutical Co is 1.23 %.

When does Ilyang Pharmaceutical Co pay dividends?

Ilyang Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Ilyang Pharmaceutical Co?

Ilyang Pharmaceutical Co paid dividends every year for the past 5 years.

What is the dividend of Ilyang Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 150 KRW are expected. This corresponds to a dividend yield of 1.23 %.

In which sector is Ilyang Pharmaceutical Co located?

Ilyang Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ilyang Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ilyang Pharmaceutical Co from 5/1/2024 amounting to 150 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did Ilyang Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of Ilyang Pharmaceutical Co in the year 2024?

In the year 2024, Ilyang Pharmaceutical Co distributed 150 KRW as dividends.

In which currency does Ilyang Pharmaceutical Co pay out the dividend?

The dividends of Ilyang Pharmaceutical Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ilyang Pharmaceutical Co

Our stock analysis for Ilyang Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ilyang Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.